Some previous studies have shown that regulation of the MAPK pathway and the downregulation of the PI3K-AKT-mTOR axis have confirmed potential therapeutic effects in cancer treatment [37,38,39]; however, more studies on both pathways are required. This evidence concerns the gene AKT1 and cancer.